FORM 12 Under the Income Tax Act 2025: A Complete Guide to Statutory R&D Reporting by the Prescribed Authority

Overview: Understanding FORM 12 in the R&D Tax Incentive Framework

The Indian tax framework governing research and development incentives has undergone significant structural refinement under the Income Tax Act, 2025. Central to this framework is FORM 12, a statutory reporting instrument prescribed under Rule 29 of the Income-tax Rules, 2026. This form serves as the official communication channel through which the prescribed authority — ordinarily the Secretary of the Department of Scientific and Industrial Research (DSIR) — submits its evaluation, certification, and expenditure findings to the Chief Commissioner of Income-tax exercising jurisdiction over the concerned company.

It is important to note at the outset that FORM 12 is not a company-filed document. Rather, it is an institutional report that operates independently of the company's own compliance obligations, forming a critical pillar in the verification and oversight of deduction claims under Section 45(2) of the Income Tax Act, 2025.

Important Note: FORM 12 under the Income-tax Rules, 2026 corresponds to the erstwhile Form 3CL under the Income-tax Rules, 1962, which was linked to Section 35 of the Income Tax Act, 1961. The new framework represents a structural continuation with enhanced electronic oversight capabilities.

Statutory and Regulatory Mapping

Before diving into the mechanics of FORM 12, it is useful to understand how the new and old frameworks align:

This mapping confirms that FORM 12 is the direct legislative successor to Form 3CL, carrying forward the same substantive purpose while being repositioned within a modernised compliance ecosystem.

Legislative Foundation: Section 45(2) and Rule 29

Section 45(2) of the Income Tax Act, 2025

Section 45(2) of the Income Tax Act, 2025 lays down the statutory basis for allowing deductions in respect of expenditure incurred on approved in-house R&D facilities. The provision recognises that genuine investment in scientific research and development by companies deserves fiscal encouragement, subject to defined eligibility conditions and procedural safeguards.

Rule 29 of the Income-tax Rules, 2026

Rule 29 of the Income-tax Rules, 2026 operationalises the broad legislative intent of Section 45(2) by prescribing the detailed procedural framework governing:

• Approval of in-house R&D facilities
• Agreement execution between the company and the prescribed authority
• Audit and examination of the approved facility
• Reporting obligations of the prescribed authority to the tax administration

FORM 12 is the instrument through which the prescribed authority discharges the reporting obligation under Rule 29, completing the final leg of the compliance lifecycle before deduction claims are verified by the Income Tax Department.

What Is FORM 12? A Functional Definition

FORM 12 is a statutory certification and reporting form submitted by the prescribed authority — the Secretary, DSIR — to the Chief Commissioner of Income-tax having territorial jurisdiction over the company whose in-house R&D facility has been examined. A copy of the form is also transmitted to the company itself for its internal records and reference.

The form serves a dual function:

1. Certification function — It certifies the nature, adequacy, and recognition status of the in-house R&D facility.
2. Quantification function — It reports the eligible capital and revenue expenditure incurred on the approved facility during the relevant tax year.

Together, these two functions make FORM 12 an authoritative technical input that the Income Tax Department relies upon when scrutinising deduction claims under Section 45(2).